Clinical trials: Antimicrobial Effectiveness
- Condition Antimicrobial Effectiveness
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Acne
Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Facial Acne
The purpose of the study is to determine the development of microbial resistance when using one of two topical acne therapies for the treatment of facial acne vulgaris.
- Trial name
- NCT00841776
- Testing
- Duac, Ziana gel
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Stiefel, a GSK Company
Skin Infections, Bacterial
Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo
The goal of this study is to determine if topical SB-275833 ointment, 1% is as safe and effective as topical sodium fusidate ointment, 2% for the treatment of impetigo in adults and children as young as 9 months of age.
- Trial name
- NCT00133874
- Testing
- SB-275833 ointment, 1%
- Where
- 69 sites in Canada, Costa Rica and 8 more
- Volunteers
- 520 people
- Sponsor
- GlaxoSmithKline
Sinusitis
The Study of Nasonex® Compared With Placebo for the Relief of Symptoms Associated With Acute Bacterial Sinusitis When Used With Antibiotics (Study P04824AM3)
The purpose of this study is to evaluate the efficacy and safety of Nasonex® (mometasone furoate nasal spray), when used together with an antibiotic, for the relief of symptoms associated with acute bacterial sinusitis.
- Trial name
- NCT00423176
- Testing
- MFNS and antibiotic
- Volunteers
- 237 people
- Sponsor
- Organon and Co
Acne Vulgaris
Efficacy and Tolerability Evaluation of a Novel Dermo-cosmetic Product for Mild-to-moderate Acne
The goal of this non-interventional, observational study is to evaluate the real-world efficacy and tolerance of a novel dermocosmetic cream containing 15% Azelaic acid and a complex of active ingredients (α-AZ cream) in patients…
- Trial name
- NCT07759505
- Where
- Romania
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- ISISPHARMA
Impetigo
Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment
The goal of this study is to determine if topical SB-275833 ointment, 1% is more effective than a placebo ointment in the treatment of primary impetigo.
- Trial name
- NCT00133848
- Testing
- SB-275833 ointment, 1%
- Where
- 22 sites in India, Italy and 3 more
- Volunteers
- 210 people
- Sponsor
- GlaxoSmithKline
Non-bullous Impetigo
A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo
The purpose of this study is to determine the efficacy of the topical antibiotic LTX-109 in terms of clinical and microbiological response in treatment of impetigo.
- Trial name
- NCT01803035
- Testing
- LTX-109 1 %, LTX-109 2 %
- Where
- 2 sites in Dominican Republic
- Volunteers
- 210 people
- Sponsor
- Lytix Biopharma AS
Antibiotic
The Efficacy and Safety of Daptomycin in the Treatment of Gram-positive Bacterial Infection.
This study aims to collect and analyze clinical data of daptomycin to explore the efficacy and safety of daptomycin in the treatment of Gram-positive bacterial infections. And optimize the dosing regimen based on these data.
- Trial name
- NCT04546815
- Testing
- Daptomycin
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Jiangsu Hengrui Pharmaceutical Co., Ltd.
Influenza, Human
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
The purpose of this study is to test the safety and efficacy of zanamivir given intravenously and how well it works at two different doses in hospitalized adolescents and adults with flu.
- Trial name
- ZORO (NCT01231620)
- Testing
- Zanamivir, Oseltamivir
- Where
- 170 sites in United States, Australia and 26 more
- Volunteers
- 626 people
- Sponsor
- GlaxoSmithKline
Cystic Fibrosis
Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa
The purpose of this study was to evaluate the safety and efficacy of aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF) and lung infection due to Pseudomonas aeruginosa (PA).
- Trial name
- AIR-CF2 (NCT00104520)
- Testing
- AZLI 75 mg two times a day (BID)/three times a day (TID)
- Where
- 56 sites in United States
- Volunteers
- 211 people
- Sponsor
- Gilead Sciences
Candidiasis, Oral, HIV Infections
The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients
To evaluate the safety and effectiveness of Peridex (an oral rinse containing chlorhexidine gluconate) for preventing the occurrence of clinically-evident microbiologically-documented oral candidiasis in HIV-positive patients…
- Trial name
- NCT00002431
- Testing
- Chlorhexidine gluconate
- Where
- 5 sites in United States
- Sponsor
- Procter and Gamble
Cystic Fibrosis, Lung Infection
Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa
The purpose of this study was to evaluate the safety and efficacy of a 28-day course of aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF), mild lung disease (forced expiratory volume in 1 second…
- Conditions
- Cystic Fibrosis, Lung Infection, Pseudomonas Aeruginosa
- Trial name
- AIR-CF4 (NCT00712166)
- Testing
- AZLI 75 mg three times daily (TID)
- Where
- 40 sites in United States, Australia and 1 more
- Volunteers
- 160 people
- Sponsor
- Gilead Sciences
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase
The purpose of this superiority study is to evaluate the efficacy and safety of exebacase in addition to standard of care antibiotics (SoCA) compared with SoCA alone for the treatment of patients with Staphylococcus aureus (S.
- Trial name
- DISRUPT (NCT04160468)
- Testing
- Exebacase
- Where
- 55 sites in United States
- Volunteers
- 259 people
- Sponsor
- ContraFect
Community-Acquired Pneumonia (CAP)
Lefamulin Post-Market Surveillance Study
Community-acquired pneumonia (CAP) refers to infectious parenchymal lung inflammation acquired outside hospital settings. In China, its incidence is 7.13 per 1000 person-years, with over 10 million new cases annually.
- Trial name
- NCT07697885
- Testing
- This is a multicenter, single-arm, non-interventional study. No interventional measures will be adopted.
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19)
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People with Weakened Immune Systems or at Increased Risk for Poor Outcomes who are Hospitalized Due to Severe COVID-19
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization
- Trial name
- EPIC-HOS (NCT05545319)
- Testing
- Nirmatrelvir, Ritonavir
- Where
- 11 sites in United States, Bulgaria
- Sponsor
- Pfizer
Diarrhea, Infantile
Preventing Antibiotic-Associated DiarRhea Using Erceflora
To determine the effectiveness of the pre-biotic Bacillus clausii in preventing antibiotic associated diarrhea among hospitalized immunocompetent Filipino children.
- Trial name
- PADRE (NCT00447161)
- Testing
- Bacillus Clausii Multi ATB Resist
- Where
- Philippines
- Volunteers
- 323 people
- Sponsor
- Sanofi
Pseudomonas Aeruginosa, Cystic Fibrosis
Open Label Extension to Bridging Study CTBM100C2303
This was an open-label, single arm (uncontrolled) study in participants suffering from cystic fibrosis, who had completed their study participation in CTBM100C2303 (all visits) and who were proven infected with Pseudomonas…
- Trial name
- NCT00982930
- Testing
- Tobramycin inhalation powder
- Where
- 2 sites in Estonia, Russia
- Volunteers
- 55 people
- Sponsor
- Novartis Pharmaceuticals
Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations
This study will evaluate the efficacy and safety of an oral ARV-1801(ACG-701) plus optimized background therapy (OBT) compared to oral placebo plus OBT, each administered for 14 days, in the treatment of participants with Cystic…
- Trial name
- REPRIEVE (NCT05641298)
- Testing
- Sodium Fusidate
- Where
- 25 sites in United States
- Sponsor
- Aceragen
Antibiotic-associated Diarrhea
Efficacy of a Probiotic Product in Children With Antibiotic-associated Gastrointestinal Disorders
To assess the effect of a probiotic product, when co-administered with antibiotics, on gastrointestinal symptoms following antibiotic treatment in children.
- Trial name
- NCT02722993
- Testing
- Probiotics
- Where
- Poland
- Volunteers
- 117 people
- Sponsor
- Probi AB
Treatment of Early Pulmonary Infections With P. Aeruginosa in Cystic Fibrosis Patients
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
This study investigated the efficacy of inhaled TOBI treatment for early infections of P. aeruginosa in paediatric patients with cystic fibrosis.
- Trial name
- EARLY (NCT01082367)
- Testing
- TOBI
- Where
- 19 sites in Canada, Egypt and 8 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Acne Vulgaris
A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)
The purpose of this study was to demonstrate that daily use of topical trifarotene (CD5789) 50 microgram per gram (mcg/g) cream when used in association with oral antibiotic is safe and effective for the treatment of severe AV.
- Trial name
- DUAL (NCT04451330)
- Testing
- Trifarotene cream, Doxycycline hyclate, Trifarotene Vehicle
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 202 people
- Sponsor
- Galderma R&D